
CLAIMS

1. A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof:



(I)


wherein: ring A is 6- to 10-membered aryl;

ring B is 4- to 7-membered heterocyclyl, wherein the 4- to 7-membered heterocyclyl contains 1-3 oxygen atoms;

L is a chemical bond;

each R^1, each R^2 are identical or different and are each independently selected from the group consisting of a hydrogen atom, halogen, cyano, nitro, oxo, alkenyl, alkynyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-OR^5$, $-C(O)R^6$, $-C(O)OR^6$, $-OC(O)R^6$, $-NHC(O)OR^6$, $-NR^7R^8$, $-C(O)NR^7R^8$, $-S(O)_rR^6$ and $-S(O)_rNR^7R^8$, wherein the alkenyl, alkynyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, cyano, amino, nitro, oxo, alkenyl, alkynyl, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy and heterocyclyloxy;

R^3 is selected from the group consisting of a hydrogen atom, halogen, cyano, nitro, alkenyl, alkynyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, $-OR^5$, $-C(O)R^6$, $-C(O)OR^6$, $-OC(O)R^6$, $-NHC(O)OR^6$, $-NR^7R^8$, $-C(O)NR^7R^8$, $-S(O)_rR^6$ and $-S(O)_rNR^7R^8$, wherein the alkenyl, alkynyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, cyano, amino, nitro, oxo, alkenyl, alkynyl, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy and heterocyclyloxy;

R^4 is  ;

ring C is selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl;


R^0 is selected from the group consisting of a hydrogen atom, hydroxy, halogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy and cycloalkyl;

each R^{4a} is identical or different and is independently selected from the group consisting of a hydrogen atom, hydroxy, halogen, cyano, nitro, oxo, alkenyl, alkynyl, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy, heterocyclyloxy and $-NR^9R^{10}$;
R^5 and R^6 are identical or different and are each independently selected from the group consisting of a hydrogen atom, alkenyl, alkynyl, alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkenyl, alkynyl, alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, cyano, amino, nitro, oxo, alkenyl, alkynyl, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy and heterocyclyloxy;
R^7, R^8, R^9 and R^{10} are identical or different and are each independently selected from the group consisting of a hydrogen atom, alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, cyano, amino, nitro, oxo, alkenyl, alkynyl, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy and heterocyclyloxy;
or R^7 and R^8, together with the N atom to which they are attached, form one heterocyclyl group; or R^9 and R^{10}, together with the N atom to which they are attached, form one heterocyclyl group; the heterocyclyl group is optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, cyano, amino, nitro, oxo, alkenyl, alkynyl, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, cycloalkyloxy and heterocyclyloxy;
p is 0, 1, 2, 3 or 4;
q is 0, 1, 2, 3 or 4;
m is 0, 1, 2, 3 or 4;
n is 0, 1, 2, 3 or 4; and
r is 0, 1 or 2.


2. The compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to claim 1, wherein ring C is aryl or heteroaryl.

3. The compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R^3 is a hydrogen atom.

4. The compound represented by general formula (I) or the pharmaceutically acceptable



salt thereof according to any of claims 1 to 3, wherein R^4 is  ; ring C is 5- to 10-membered heteroaryl, preferably 5- or 6-membered heteroaryl; R^{4a} and n are as defined in claim 1.

5. The compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to any of claims 1 to 4, being a compound represented by general formula (II) or a pharmaceutically acceptable salt thereof:




(II)

wherein:
ring C is 5- to 10-membered heteroaryl, preferably 5- or 6-membered heteroaryl;
ring A, ring B, L, R^1, R^2, R^{4a}, p, q and n are as defined in claim 1.

6. The compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to any of claims 1 to 5, wherein ring A is selected from the group consisting of phenyl,  and  ; preferably, ring A is phenyl.

7. The compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to any of claims 1 to 6, wherein ring B is 5- or 6-membered heterocyclyl, wherein the 5- or 6-membered heterocyclyl contains 1 or 2 oxygen atoms.

8. The compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to any of claims 1 to 7, being a compound represented by general formula (III) or a pharmaceutically acceptable salt thereof:



(III)

wherein:

X is selected from the group consisting of O, CR^aR^b and C=O;
each R^a, R^b, R^c and R^d is identical or different and is independently selected from the group consisting of a hydrogen atom, hydroxy, halogen, cyano, amino, alkenyl, alkynyl, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkyloxy and heterocyclyloxy;
or R^c and R^d, together with the carbon atom to which they are attached, form one C=O;
s is 0, 1, 2 or 3; n is 0, 1, 2, or 3;
L, R^1, R^{4a}, and p are as defined in claim 1.

9. The compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to claim 8, wherein R^c and R^d are identical or different and are each independently hydrogen atoms or halogens.

10. The compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to claim 8 or 9, wherein X is O or CH_2.

11. The compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to any of claims 8 to 10, wherein s is 1 or 2.


12. The compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to any of claims 1 to 11, wherein each R^1 is identical or different and is independently selected from the group consisting of a hydrogen atom, hydroxy, halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} alkoxy C_{1-6} alkyl, and $-C(O)OCH_3$ and $-NR^7R^8$; R^7 and R^8 are identical or different and are each independently hydrogen atoms or C_{1-6} alkyl; preferably, each R^1 is identical or different and is independently selected from the group consisting of a hydrogen atom, halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy and $-NR^7R^8$; R^7 and R^8 are identical or different and are each independently hydrogen atoms or C_{1-6} alkyl; more preferably, each R^1 is identical or different and is independently C_{1-6} alkoxy.

13. The compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to any of claims 1 to 7 and 12, wherein each R^2 is identical or different and is independently selected from the group consisting of a hydrogen atom, halogen, C_{1-6} alkyl and C_{1-6} alkoxy, and is preferably a hydrogen atom or halogen, and is more preferably a hydrogen atom.


14. The compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to any of claims 1 to 13, wherein each R^{4a} is identical

or different and is independently selected from the group consisting of a hydrogen atom, hydroxy, halogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl and C_{1-6} alkoxy, and is preferably a hydrogen atom.


15. The compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to any of claims 1 to 14, being selected from the group consisting of the following compounds:




1 ,




2 ,




3 ,




4 ,




6 ,




7 ,




8 ,




9 ,




10 ,




11 ,




12 ,




13 ,





14 ,





15 ,





16 , 


17 , 


18 , 


19 , 


20 , 


21 , 


22 , 


23 , 


24 , 


24c , 


, 


, 

24d , 

, 


, 

25 , 

, 


,

26 ,

26-1 and 

26-2 .


16. A compound represented by general formula (IA) or a salt thereof:




(IA)

wherein:
ring B, R^2, R^3, R^4 and q are as defined in claim 1.


17. A compound or a salt thereof, selected from the group consisting of the following compounds or salts thereof:




1n ,




2c ,




2d ,




2f ,




2g ,




4h ,



5f ,




24b and



25c .

18. A method for preparing the compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to claim 1, wherein the method comprises:



(IA) (IB) (I)

reacting a compound represented by general formula (IA) or a salt thereof with a compound represented by general formula (IB) or a salt thereof to give the compound

represented by general formula (I) or the pharmaceutically acceptable salt thereof, wherein:
ring A, ring B, L, R^1 to R^4, p and q are as defined in claim 1.

19. A pharmaceutical composition, wherein the pharmaceutical composition comprises the compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to any of claims 1 to 15, and one or more pharmaceutically acceptable carriers, diluents or excipients.

20. Use of the compound represented by general formula (I) or the pharmaceutically acceptable salt thereof according to any of claims 1 to 15 or the pharmaceutical composition according to claim 19 in the preparation of a medicament for treating and/or preventing a cancer, wherein the cancer is selected from the group consisting of lung cancer, mesothelioma, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, brain cancer, melanoma, anal cancer, liver cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, ovarian cancer, vaginal cancer, vulvar cancer, Hodgkin's lymphoma, esophageal cancer, colorectal cancer, small intestine cancer, stomach cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, penile cancer, testicular cancer, prostate cancer, leukemia, B-cell lymphoma, bladder cancer, urethral cancer, ureter cancer, renal cell carcinoma, renal pelvis cancer, central nervous system tumor (CNS), primary CNS lymphoma, spinal cord tumor, glioblastoma, cerebral glioma, pituitary adenoma and squamous cell carcinoma; and is preferably selected from the group consisting of breast cancer, prostate cancer, lung cancer, pancreatic cancer, ovarian cancer, cervical cancer, endometrial cancer, bladder cancer, cerebral glioma, B-cell lymphoma, liver cancer and leukemia, wherein the breast cancer is preferably ER^+ breast cancer or $ER^+/HER2^-$ breast cancer; the lung cancer is preferably non-small cell lung cancer; the prostate cancer is preferably castration-resistant prostate cancer.